Please assess the completion status of the following clinical trial:

Trial Title: Open-label Study of Anakinra in MPS III

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* MPS III~* ≥ 4 years of age~* Patient or parent/legal guardian is able and willing to provide informed consent. For patients 7 to 17 years of age, assent must also be provided when cognitively possible.~* If on Genistein, must have been on a stable dose for 6 months prior to enrollment~* If on melatonin or other sleep medications, must have been on stable doses for the past 3 months~Exclusion Criteria:~* Currently enrolled in another ongoing clinical treatment trial~* Previous or current treatment with anakinra, canakinumab or any other IL-1 inhibitor.~* Use of the following therapies prior to enrollment:~  * Narcotic analgesics within 24 hours prior to enrollment.~ * Tocilizumab, dapsone or mycophenolate mofetil within 3 weeks prior to enrollment.~ * Etanercept, leflunomide, thalidomide, or cyclosporine or intraarticular, intramuscular, intravenous, or oral administration of glucocorticoids within 4 weeks prior to enrollment.~ * Intravenous immunoglobulin (IVIG), adalimumab, or methotrexate within 8 weeks prior to enrollment.~ * Infliximab, 6-mercaptopurine, azathioprine, cyclophosphamide or chlorambucil within 12 weeks prior to enrollment.~ * Rituximab within 26 weeks prior to enrollment~* Live vaccines within 1 month prior to enrollment.~* Known presence or suspicion of active, chronic or recurrent serious bacterial, fungal or viral infections, including tuberculosis, HIV infection or hepatitis B or C infection.~* Clinical evidence of liver disease or liver injury as indicated by presence of abnormal liver tests:~  * AST or ALT \> 5 x ULN, or~ * AST or ALT \> 3 x ULN accompanied by elevated bilirubin \>2 x ULN.~* Presence of severe renal function impairment (estimated creatinine clearance \< 30 mL/min/1.73m2).~* Presence of neutropenia.~* History of malignancy.~* Known hypersensitivity to E coli-derived proteins, or any components of Kineret® (anakinra).~* Pregnant or lactating women.~* Current active infection;~* History of serious opportunistic infection (e.g., bacterial \[Legionella and Listeria\]; tuberculosis \[TB\]; invasive fungal infections; or viral, parasitic, and other opportunistic infections);~* Positive TB skin test, positive Quantiferon-TB Gold TB test, positive chest X-ray, or a recent exposure to TB~* Requirement for live vaccine exposure that would be expected to occur during the time frame of the study

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- treatment (Type: EXPERIMENTAL): anakinra 100 mg subcutaneous once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).